Evidence map›Paper›PMID 33076270›Full record

ArticleInternational journal of molecular sciences2020

Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.

Susanne Berchtold, Julia Beil, Christian Raff, Irina Smirnow, Martina Schell, Janina D'Alvise, Silvia Gross, Ulrich M Lauer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Susanne BerchtoldDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
Julia BeilDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.ORCID 0000-0002-6884-8249
Christian RaffDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
Irina SmirnowDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
Martina SchellDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
Janina D'AlviseCore Facility for Medical Bioanalytics, Institute for Ophthalmic Research, University Hospital Tübingen, D-72076 Tübingen, Germany.
Silvia GrossDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
Ulrich M LauerDepartment of Internal Medicine VIII, University Hospital Tübingen, D-72076 Tübingen, Germany.
University Children's Hospital Tübingen · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically modified vaccinia viruses (VACVs) have been shown to possess profound oncolytic capabilities. However, tumor cell resistance to VACVs may endanger broad clinical success. Using cell mass assays, viral replication studies, and fluorescence microscopy, we investigated primary resistance phenomena of cell lines of the NCI-60 tumor cell panel to GLV-1h94, a derivative of the

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsCell DeathCell Line, TumorCombined Modality TherapyCytosine DeaminaseFlucytosineFluorouracilGenetic EngineeringHumansOncolytic VirotherapyOncolytic VirusesProdrugsVaccinia virusViral ProteinsAntineoplastic AgentsCytosine DeaminaseFlucytosineFluorouracilProdrugsViral Proteins5-fluorocytosinechemovirotherapyNCI-60 tumor cell paneloncolytic virotherapysuper cytosine deaminase prodrug systemvaccinia virusvirotherapy resistance

Identifiers

PMID33076270
PMCPMC7589280
OpenAlexW3093392566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.